CytoMed Therapeutics (GDTC) Non-Current Debt (2021 - 2025)

CytoMed Therapeutics has disclosed Non-Current Debt across 5 years of filings, most recently posting $284446.8 for Q4 2025.

• In Q4 2025, Non-Current Debt fell 4.04% year-over-year to $284446.8; the TTM figure through Dec 2025 stood at $284446.8 (down 4.04% YoY), while the FY2025 annual figure was $40847.0, up 8.49% from the prior year.
• Non-Current Debt came in at $284446.8 for Q4 2025 at CytoMed Therapeutics, up from $38264.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $397270.9 in Q4 2021 to a low of $37389.0 in Q2 2024.
• Average Non-Current Debt over 5 years is $216827.5, with a median of $290439.9 recorded in 2024.
• Year-over-year, Non-Current Debt slipped 14.97% in 2022 and grew 2.34% in 2025.
• Over 5 years, Non-Current Debt stood at $397270.9 in 2021, then fell by 14.97% to $337818.9 in 2022, then dropped by 10.59% to $302033.6 in 2023, then declined by 1.85% to $296433.0 in 2024, then declined by 4.04% to $284446.8 in 2025.
• Per Business Quant data, the three most recent Non-Current Debt figures were $284446.8 in Q4 2025, $38264.0 in Q2 2025, and $296433.0 in Q4 2024.